Introduction
Every hemp manufacturer faces a portfolio decision in 2026 that they can make proactively, or have made for them by November 12.
The hemp products that were viable in 2025 divide into three categories under the new framework: those that will continue unchanged, those that can survive with reformulation, and those that will no longer be viable after November. The brands that perform this segmentation consciously — and act on it — will have clarity, continuity, and competitive positioning when the deadline hits.
The brands that don't will face a scramble: discovering on or after November 12 which products are no longer viable, managing unexpected inventory write-downs, and explaining to their distribution partners why their catalog just contracted without warning.
This article provides a practical framework for hemp portfolio segmentation in advance of 2026.
The Three Categories of Post-2026 SKUs
The first step in portfolio architecture is classifying every active SKU into one of three categories based on its compliance status under the 0.4mg/container total THC limit:
Category 1 — Continue As-Is: Products that are already compliant, with meaningful margin below the 0.4mg limit, using ingredients whose batch variability keeps them reliably compliant. These products require documentation updates and ongoing monitoring, but not reformulation.
Category 2 — Reformulate to Survive: Products that are close to or over the 0.4mg limit but whose consumer value proposition can be preserved with reformulation — a different ingredient, a lower loading, a formula adjustment. These products have a path to compliance with investment.
Category 3 — Retire or Transform: Products that either cannot be reformulated to compliance while maintaining their core value proposition (high-THC intoxicating products, for example), or whose primary consumer appeal is tied to intoxication levels that exceed the new framework. These products need a plan that ends with them off shelves or fundamentally transformed.
Honest categorization is the prerequisite for honest planning.
How to Run the Compliance Segmentation
For each SKU, the compliance segmentation process requires three inputs:
- Current total THC per container: Calculate this from your ingredient COAs and formulation records. Use the formula: Total THC% × ingredient loading per container (mg) ÷ 100.
- Reformulation potential: If the current product exceeds 0.4mg, can the formulation be adjusted to meet compliance while maintaining product quality and consumer appeal?
- Category viability: Is the product's consumer value proposition tied to compliance-friendly attributes (functional wellness, sleep, focus, etc.) or to intoxication that the new framework restricts?
The output is a SKU-by-SKU classification table with compliance status, reformulation path, and strategic recommendation for each product. This table becomes the roadmap for your supply chain repositioning, reformulation timeline, and inventory transition plan.
Strategic Planning by SKU Category
Category 1 products (compliant, continue as-is) still require active management:
- Update documentation to reflect the per-container compliance calculation
- Establish a monitoring program for ongoing batch compliance
- Brief your distribution partners on the compliance status of these products proactively
- Consider marketing these products' compliance status as a positive differentiator
Category 2 products (reformulate to survive) require the most active investment:
- Prioritize reformulation for your highest-revenue SKUs first
- Set a reformulation completion deadline of no later than July 2026
- Engage your ingredient suppliers on specification requirements before committing to a reformulation direction
- Retest reformulated products against the per-container compliance standard before full production
Category 3 products (retire or transform) require a wind-down plan:
- Calculate your unsold inventory exposure for each product
- Model the sell-through timeline and latest viable manufacturing date
- Brief retail and distribution partners on product discontinuation with adequate lead time
- Explore whether product IP, branding, or formulation work can be redirected into a Category 2 reformulation
The Market Opportunity Hidden in Portfolio Reduction
Counterintuitively, the post-2026 portfolio reduction is a market opportunity for brands that navigate it well.
As products with non-compliant THC profiles exit the market, shelf space opens up. Distribution relationships held by non-compliant brands become available. Consumer demand for wellness and functional hemp products doesn't disappear — it concentrates on the remaining compliant brands.
Brands that enter Q4 2026 with a fully compliant SKU portfolio, proactive distribution partner communication, clear compliance documentation, and well-positioned messaging around safety and transparency will be positioned to capture market share from brands that didn't plan ahead.
The brands that lose revenue from portfolio reduction are those who don't replace it with anything. The brands that replace it with compliant products and distribution relationships will gain revenue from others' losses.
Communicating Portfolio Changes to Distribution Partners
One of the most underestimated challenges in 2026 portfolio management is the distribution communication problem.
Retailers and distributors need to know:
- Which products in your current catalog will remain available
- Which products are being reformulated (and on what timeline)
- Which products are being discontinued
- What compliance documentation exists for continuing products
Brands that communicate proactively — delivering category breakdowns, compliance documentation, and reformulation timelines to distribution partners before being asked — build trust and maintain shelf space. Brands that communicate reactively risk losing shelf allocation to more organized competitors.
Distribution communication should begin by June at the latest — ideally earlier for accounts with long buyer approval processes.
Low Gravity Hemp Perspective
At Low Gravity Hemp, we're helping our manufacturing partners work through this exact segmentation process — identifying which of their SKUs need ingredient changes to remain compliant, and which are already well-positioned.
Our product portfolio covers the ingredient needs for both Category 1 and Category 2 SKUs: isolates and tightly-specified broad spectrum for products that need to stay under 0.4mg with confidence.
If you're building your 2026 portfolio architecture and need to understand what ingredient specifications support each category of your product line, we're ready for that conversation.
Final Thoughts
Portfolio architecture in 2026 is not a creative exercise — it's a survival strategy. The brands that perform it honestly, act on it decisively, and communicate it proactively to their distribution partners will be significantly better positioned than those who don't. The window for doing it thoughtfully closes in the coming months.
👉 Visit lowgravityhemp.com to explore our compliance-ready ingredient portfolio and talk to our B2B team about your 2026 product architecture needs.
